Advertisement
Singapore markets closed
  • Straits Times Index

    3,307.90
    -6.15 (-0.19%)
     
  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     
  • Dow

    39,806.77
    -196.82 (-0.49%)
     
  • Nasdaq

    16,794.88
    +108.91 (+0.65%)
     
  • Bitcoin USD

    71,032.55
    +3,900.87 (+5.81%)
     
  • CMC Crypto 200

    1,533.05
    +44.51 (+2.99%)
     
  • FTSE 100

    8,394.08
    -30.12 (-0.36%)
     
  • Gold

    2,423.40
    -15.10 (-0.62%)
     
  • Crude Oil

    78.73
    -1.07 (-1.34%)
     
  • 10-Yr Bond

    4.4370
    +0.0170 (+0.38%)
     
  • Nikkei

    38,946.93
    -122.75 (-0.31%)
     
  • Hang Seng

    19,220.62
    -415.60 (-2.12%)
     
  • FTSE Bursa Malaysia

    1,622.09
    -5.41 (-0.33%)
     
  • Jakarta Composite Index

    7,186.04
    -80.65 (-1.11%)
     
  • PSE Index

    6,633.66
    -49.12 (-0.74%)
     

Ultimovacs ASA – Annual General Meeting held on April 18, 2024

Ultimovacs ASA
Ultimovacs ASA

Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved.

The following board members were re-elected for a period of one year, and the Board of Directors will consist of the following persons:

  • Jónas Einarsson, Chair of the Board

  • Henrik Schüssler, board member

  • Kari Grønås, board member

  • Ketil Fjerdingen, deputy board member

The Nomination Committee will consist of the following persons until the Annual General Meeting in 2025:

  • Ole Kristian Hjelstuen, Chair of the committee

  • Hans Peter Bøhn, committee member

The minutes from the meeting are enclosed and available at the company’s website.

ADVERTISEMENT

For further information, please see www.ultimovacs.com or contact:

Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA

Email: je@radforsk.no

Phone: +47 480 96 355

Carlos de Sousa, CEO

Email: carlos.desousa@ultimovacs.com

Phone: +47 908 92507

        

Anne Worsøe, Head of IR & Communication

Email: anne.worsoe@ultimovacs.com

Phone: +47 906 86815


Attachment